+1 (202) 780-3397
TAVR 2017: Supporting data and future directions
Annual Conference on HEART DISEASES
September 18-19, 2017 | Toronto, Canada
Nicholas Ruggiero II
Thomas Jefferson University Hospital, USA
Keynote : Curr Trend Cardiol
Abstract:
Transcatheter Aortic Valve Replacement (TAVR), first performed by Dr. Cribier in 2002, has become the management of choice for patients with aortic stenosis who are considered high risk or inoperable. Current data illustrates that TAVR is equivalent to surgical aortic valve replacement (SAVR) in patients considered intermediate risk and may even be superior in specific patient populations. Ongoing trials evaluating this modality in low risk patients, asymptomatic patients as well as longitudinal data looking at valve durability will determine whether it will become the gold standard in all patient populations. In this lecture I will review the current supporting data and discuss what is on the horizon for TAVR.
Biography:
Nicholas J. Ruggiero II, was born and raised in Wilkes-Barre, PA. He graduated summa cum laude from King’s College in Wilkes Barre, PA majoring in Biology and minoring in Molecular Genetics. He then attended Jefferson Medical College where he graduated Magna Cum Laude. He was recruited back to Jefferson to begin his own section as the director of structural heart disease and non-coronary interventions. He developed the transcatheter aortic valve replacement (TAVR) program, mitraclip program, is director of the Jefferson Heart Institute vascular laboratory and is the associate program director of the Cardiology fellowship. He has published over 40 peer reviewed papers, authored numerous book chapters and abstracts, edited multiple textbooks, delivered multiple lectures at national and international meetings, served on many national and international committees and is on the editorial board of multiple journals. He is a fellow of many medical societies and is currently at the rank of associate professor at the Sidney Kimmel Medical College.
PDF HTML